NCT/Study#
NCT04196491 /
BB-2121-MM-004
A Phase 1, Open-Label, Multicenter Study To Evaluate The Safety Of Bb2121 In Subjects With High Risk, Actively Diagnosed Multiple Myeloma (Karmma-4)
DISEASE GROUP:
Multiple Myeloma
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
